Gilead Sciences (GILD) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for Gilead Sciences (GILD) over the last 10 years. The current PE ratio for Gilead Sciences as of August 21, 2017 is 7.18.
|Medical||Medical - Biomedical and Genetics||$94.170B||$30.390B|
|Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugsthat are safer, easier for patients to tolerate and more effective.|